CSW Industrials reports historic revenue following three strategic acquisitions, including its largest ever. However, integration costs and rising interest expenses pressure margins, leading the firm to miss earnings expectations as its stock faces recent headwinds.
CNH Industrial is capturing investor attention with its strategic push into automation, highlighted by the new R4 autonomous robot, and a stable demand outlook for its core agriculture and construction segments. This comes as the market weighs the company's recent stock momentum against contrasting valuation models.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.
The commencement of sea trials for the nuclear-powered aircraft carrier USS John F. Kennedy coincides with the 140th anniversary of its builder, Newport News Shipbuilding, underscoring Huntington Ingalls Industries' entrenched role in U.S. naval defense and its long-term investment profile.
As sky-high valuations plague pure-play AI stocks, a global industrial landlord is emerging as a critical—and potentially undervalued—enabler of the artificial intelligence boom through its strategic pivot into data centers.
Realty Income, the renowned monthly dividend payer, is making a strategic pivot by acquiring industrial assets in Mexico and establishing a new fee-based asset management business for institutional investors, signaling a significant expansion beyond its core U.S. retail net-lease portfolio.
Industrial equipment maker Graco (NYSE: GGG) is expanding its powder technology footprint through the acquisition of Color Service, a specialist in gravimetric dosing. The move coincides with the company reporting record quarterly sales, fueled by organic growth and strategic integrations, signaling a period of focused expansion for the Minnesota-based firm.
Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.
Six Italian police and coastguard members face trial for alleged negligence in the Cutro shipwreck that killed at least 94 migrants, a case testing Italy's hardline migration policies.
TAIPEI, Jan 30 (Reuters) - Taiwan completed the maiden underwater sea trial for its first domestically developed submarine on Thursday, a big milestone in a project aimed at strengthening deterrence
Brendan Banfield's murder trial reaches its climax Friday with closing arguments after he testified he shot a man he found stabbing his wife. Prosecutors allege an elaborate murder-for-hire plot, while the defense claims a tragic act of self-defense.
Federal authorities have lodged an immigration detainer for a man charged with the brutal rape of an autistic teenager in Cathedral City, calling the case 'exceptionally heinous' and urging California officials to cooperate.
Voyager Technologies has commenced a significant expansion of its defense manufacturing facility in Pueblo, Colorado, marking one of the region's largest military-industrial investments in recent years. The project aims to bolster domestic production for missile defense and munitions, integrating advanced automation and AI-driven logistics.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Fortive Corporation's shares have retreated over 5% in the past month, prompting investors to re-examine the industrial technology conglomerate's fundamentals. With a renewed focus on its recurring revenue streams and a fair value estimate suggesting upside, analysts are divided on whether the pullback presents a buying opportunity or reflects deeper sector headwinds.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Marius Borg Høiby, son of Crown Princess Mette-Marit, was arrested on new violent charges days before his rape trial, casting a shadow over the monarchy just as his mother faces renewed criticism over her past association with Jeffrey Epstein.
Crown Holdings (CCK) is scheduled to report its fourth-quarter earnings after Wednesday's market close, with analysts projecting modest revenue growth and steady profitability as the metal packaging giant navigates shifting demand and competitive pressures.
